Alder Biopharmaceuticals Inc (ALDR) Files Form 4 Insider Selling : Mark James Litton Sells 6,000 Shares

Alder Biopharmaceuticals Inc (ALDR): Mark James Litton , Chief Business Officer of Alder Biopharmaceuticals Inc sold 6,000 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $29.25 per share for a total value of $173,663.53 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 7, 2016, Jeffrey T L Smith (Sr. VP Translational Medicine) sold 16,090 shares at $30.87 per share price.On Jun 3, 2016, Randall C Schatzman (President and CEO) sold 10,000 shares at $29.88 per share price.Also, On Jun 3, 2016, John A Latham (Chief Scientific Officer) sold 10,000 shares at $30.02 per share price.On Jun 1, 2016, Mark James Litton (Chief Business Officer) sold 25,000 shares at $30.05 per share price.

Shares of Alder Biopharmaceuticals Inc (ALDR) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.45 points or -1.56% at $28.34 with 5,56,225 shares getting traded. Post opening the session at $29.15, the shares hit an intraday low of $28.11 and an intraday high of $29.295 and the price vacillated in this range throughout the day. The company has a market cap of $1,416 M and the number of outstanding shares has been calculated to be 4,99,71,008 shares. The 52-week high of Alder Biopharmaceuticals Inc is $54.9 and the 52-week low is $15.8201.

Alder Biopharmaceuticals Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Alder Biopharmaceuticals Inc is Resumed by Wells Fargo to Outperform. The Rating was issued on Apr 21, 2016.Alder Biopharmaceuticals Inc is Initiated by Brean Capital to Buy and the brokerage firm has set the Price Target at $45. The Rating was issued on Apr 20, 2016.

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.

Leave a Reply

Alder Biopharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alder Biopharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.